Heidelberg Pharma AG

M&A Activity • Aug 17, 2010

News Details

Corporate | 17 August 2010 14:45

WILEX AG: Mandatory takeover offer from dievini Hopp BioTech has ended

WILEX AG / Offer

17.08.2010 14:45

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

WILEX AG: Mandatory takeover offer from dievini Hopp BioTech has ended

Munich, Germany, 17 August 2010. WILEX AG (ISIN DE0006614720 / WL6 /
Frankfurt Stock Exchange) was informed of the final result of the mandatory
takeover offer made to all WILEX shareholders by dievini Hopp BioTech
holding GmbH & Co. KG, Walldorf, Germany. During the course of the offer,
which expired on 12 August 2010, a total 22,953 shares were tendered at a
price of EUR 4.10. This represents 0.12% of the issued share capital (EUR
18,413,035.00) and voting rights of WILEX AG.

Consequently, the stake of dievini Hopp BioTech in WILEX increased to a
total of 6,587,990 shares and approximately 35.78% of the total share
capital respectively. dievini Hopp BioTech thus remains the largest
shareholder of WILEX, followed by UCB Pharma S.A. with 18.05%, TVM Capital
Funds with 5.03% and Merlin Biosciences Funds with 4.63%. Accordingly the
free float of WILEX is 36.51 % of the issued share capital.

About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich and is listed at
the Frankfurt Stock Exchange at the Regulated Market / Prime Standard.
WILEX's mission is to develop drugs with a low side effect profile and
targeted treatment of different types of cancer as well as diagnostic
agents for specific detection of tumours. The Company's product candidates
are based on antibodies and small molecules. WILEX has an attractive
product pipeline which includes both drug and diagnostic candidates: A
pivotal Phase III study with REDECTANE(R) has been completed and positive
data published. RENCAREX(R) is undergoing a Phase III registration trial.
Positive MESUPRON(R) Phase II data in the indication pancreatic cancer have
been published and another Phase II trial in breast cancer is ongoing. The
MEK inhibitor WX-554 has completed a Phase I trial. A further oncology
project (PI3K inhibitor WX-037) is in preclinical development and three
antibody programmes are in research. WILEX aims within a few years to be
able to finance its research and development programmes from its operating
cash flow. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 /
Symbol WL6

Contact
WILEX AG
Corporate Communications
Katja Arnold (CIRO)
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-Mail: investors@wilex.com

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

17.08.2010 Ad hoc announcement, Financial News and Press Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in München, Berlin, Düsseldorf, Stuttgart

End of News DGAP News-Service

---